CMPX
NASDAQ · Biotechnology
Compass Therapeutics Inc
$5.44
+0.11 (+2.06%)
Financial Highlights (FY 2026)
Revenue
1.15M
Net Income
-66,446,946
Gross Margin
—
Profit Margin
-5,808.8%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 41.5% | 41.5% | 41.5% |
| Operating Margin | -6,661.8% | -20.6% | -21.6% | -19.3% |
| Profit Margin | -5,808.8% | -23.4% | -25.2% | -20.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.15M | 182.11M | 191.80M | 150.00M |
| Gross Profit | — | 75.65M | 79.68M | 62.32M |
| Operating Income | -76,362,022 | -37,527,635 | -41,476,258 | -29,022,469 |
| Net Income | -66,446,946 | -42,646,254 | -48,286,720 | -30,029,624 |
| Gross Margin | — | 41.5% | 41.5% | 41.5% |
| Operating Margin | -6,661.8% | -20.6% | -21.6% | -19.3% |
| Profit Margin | -5,808.8% | -23.4% | -25.2% | -20.0% |
| Rev Growth | — | -8.0% | +10.9% | +1.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 190.71M | 178.18M | 172.82M |
| Total Equity | — | 650.14M | 615.47M | 679.35M |
| D/E Ratio | — | 0.29 | 0.29 | 0.25 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -75,469,235 | -49,107,977 | -55,425,546 | -48,007,831 |
| Free Cash Flow | — | -37,978,554 | -43,960,363 | -47,756,173 |